I just wrapped up a productive week at the 2025 JP Morgan Healthcare Conference, where the world’s biopharma industry converges in San Francisco to find opportunities for dealmaking, advance promising science, and accelerate new medicines for patients.
It’s clear the industry is at a pivotal moment – a golden age for patients, marked by unprecedented innovation. Financially, the sector is also bouncing back after several difficult years. However, as an industry, we await how the Trump administration will implement health-related policies. Here are the key trends I anticipate shaping the biopharma landscape in 2025:
To learn more: 5 Insights From The 2025 JP Morgan Healthcare Conference
